Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Procedures to be eased for new medicines from overseas

    By Hu Yongqi | China Daily | Updated: 2018-06-26 10:46
    Share
    Share - WeChat

    Approval measures will be simplified, especially for treatment of serious diseases and illness, within a matter of months

    The approval process will be eased for new medicines from overseas, especially for those treating rare diseases and life-threatening ailments.

    A State Council executive meeting, presided over by Premier Li Keqiang on Wednesday, decided to further simplify approval procedures for imported drugs, reduce prices for anti-cancer drugs and strengthen work to secure the supply of desperately-needed medicines.

    A slew of measures will be taken to make approvals easier for medicines to cure rare diseases and life-threatening illnesses, a statement released after the meeting said.

    Approval procedures should be completed in three months for rare-disease medicines and six months for those to help combat life-threatening illnesses. Meanwhile, prices for anti-cancer medicines will be reduced following the zero-tariff policy adopted last month. An alert system for precautions against supply shortages will be further enhanced, and drug reserves will be substantially expanded.

    The decision made at the meeting will allow new drugs that are already sold in overseas markets to be used on the Chinese mainland. The meeting was the latest move following the zero-tariff policy for anti-cancer drugs and the central government's encouragement of medical innovation.

    This is an urgent matter closely related to people's well-being and administrative streamlining in the pharmaceutical industry, Li said at Wednesday's meeting. Therefore, all related government departments should prioritize it and help make high-quality medicines widely available and affordable in China, he said.

    Issues such as rare-disease medications should top the government's agenda and an adequate supply of medicine should be guaranteed, Li said.

    Simplified approvals will see China no longer lag behind many countries in introducing new medicines, said Chen Yuming, a public health professor at Sun Yat-sen University in Guangzhou, capital of Guangdong province.

    Among 415 new medicines approved for sale in developed economies over the past 10 years, 76 have been approved to be sold in China and another 201 are in the stage of clinical trials and applications, according to the National Drug Administration of China.

    For medicines that have been sold in overseas markets for rare and life-threatening diseases, the time to enter the Chinese market can be shortened by one to two years when no ethnical differences are found, said Jiao Hong, head of the National Drug Administration of China, at a policy briefing on Friday hosted by the State Council Information Office. No clinical trials will be required for these medicines and experimental data collected in other countries can be used for applications, she said.

    "For medicines treating rare diseases, AIDS and cancers, we will accelerate the administrative approvals to shorten the time by one or two years for them to be sold in the Chinese market and meet the demands of Chinese patients," Jiao said.

    In October last year, the former China Food and Drug Administration lifted the restriction that applications must be submitted in China after new medicines are already sold in the country of origin. The move will encourage synchronous sales of new medicines developed in overseas markets, the CFDA said.

    Since April, imported chemical pharmaceuticals are no longer tested in trading ports but are randomly checked on the market by the authorities.

    Reforms like these have resulted in increasing numbers of medical innovations and new medicines, said Wang Lifeng, director of the administration's department of cosmetics registration management. Taking chemical pharmaceutical products as an example, the number of innovative medicines increased by 66 percent year-on-year in 2017 to 149, he said.

    For some medicines that are in urgent need, the approval process should be accelerated, which will reduce costs for pharmaceutical companies and financial burdens for patients, Chen at Sun Yat-sen University said.

    However, the use of medicines must be based on time-consuming clinical trials and ethnical differences must be taken into consideration, he said. In addition, compliance oversight should be strengthened by training professionals to check medicines available on the market, he added.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    中文字幕一区二区三区精彩视频| 久久精品无码一区二区三区免费| 国产羞羞的视频在线观看 国产一级无码视频在线 | 中文字幕一区二区人妻| 秋霞鲁丝片Av无码少妇| 日韩精品无码一区二区三区四区| 亚洲AV无码一区二区三区在线观看 | 国产精品无码无需播放器| 中文字幕无码不卡免费视频| 亚洲一区二区无码偷拍| 国产亚洲精品无码成人| 亚洲av永久无码精品秋霞电影影院| 最近2019年中文字幕6| 欧美乱人伦中文字幕在线| 嫩草影院无码av| 成在人线AV无码免观看麻豆| 国产亚洲AV无码AV男人的天堂| 亚洲国产成人片在线观看无码| 中文字幕在线观看日本| 久久中文骚妇内射| 色综合久久中文字幕无码| 最好的中文字幕视频2019| 无码人妻丰满熟妇啪啪| 免费无遮挡无码视频在线观看| 国产精品多人p群无码| 韩国免费a级作爱片无码| 蜜芽亚洲av无码精品色午夜| 未满小14洗澡无码视频网站| 亚洲gv猛男gv无码男同短文| 无套中出丰满人妻无码| 亚洲AV中文无码字幕色三| 色爱无码AV综合区| 国产精品99精品无码视亚| 国产a v无码专区亚洲av| 免费一区二区无码视频在线播放 | 亚洲Av无码国产情品久久| 久久久久无码专区亚洲av| 日韩乱码人妻无码中文字幕视频| 无码人妻丰满熟妇啪啪| 亚洲va中文字幕无码久久| www日韩中文字幕在线看|